ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m. EST.
I-Mab Conference Call Information
Investors and analysts are invited to join the conference call at 8:00 a.m. EST on August 17 via Zoom:
Link: https://i-mabbiopharma.zoom.us/j/87349766033?pwd=bFhVejFDS1dHeWw3eklaeW1JcFhpUT09
Meeting ID: 873 4976 6033
Password: 194422
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biopharmaceutical company exclusively focused on bringing transformational medicines to patients around the world through the discovery, development, and potential commercialization of novel or highly differentiated immunotherapies and biologics for oncology. I-Mab's innovative pipeline, including five key clinical assets and a pipeline of early-stage clinical and pre-clinical stage drug candidates are driven by the internal R&D's Fast-to-Proof-of-Concept and Fast-to-Market development strategies and through global partnerships. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn, Twitter, and WeChat.
I-Mab Contacts
|
|
Richard Yeh Chief Operating Officer, interim Chief Financial Officer This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloake898ff31baca86ae587073b261d3bd75').innerHTML += ''+addy_texte898ff31baca86ae587073b261d3bd75+'<\/a>'; | Gigi Feng Chief Communications Officer This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak2b84af4c12d004dff57c3a98ad5e521c').innerHTML += ''+addy_text2b84af4c12d004dff57c3a98ad5e521c+'<\/a>'; |
| Last Trade: | US$2.10 |
| Daily Change: | -0.06 -2.78 |
| Daily Volume: | 159,718 |
| Market Cap: | US$171.490M |
July 17, 2025 June 30, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
